Kenvue Inc. (NYSE:KVUE) Receives Consensus Rating of “Hold” from Brokerages

Shares of Kenvue Inc. (NYSE:KVUE) have received an average rating of “Hold” from the sixteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $24.85.

KVUE has been the topic of a number of recent research reports. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research note on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. Royal Bank of Canada dropped their price objective on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. JPMorgan Chase & Co. decreased their price objective on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 9th. Sanford C. Bernstein initiated coverage on shares of Kenvue in a research note on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. Finally, William Blair assumed coverage on Kenvue in a research note on Wednesday, April 3rd. They issued a “market perform” rating on the stock.

Institutional Trading of Kenvue

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. acquired a new stake in shares of Kenvue during the third quarter worth about $2,944,816,000. FMR LLC lifted its position in Kenvue by 572.1% during the 3rd quarter. FMR LLC now owns 89,182,980 shares of the company’s stock worth $1,790,794,000 after acquiring an additional 75,913,107 shares during the period. Wellington Management Group LLP lifted its position in Kenvue by 576.1% during the 3rd quarter. Wellington Management Group LLP now owns 71,686,830 shares of the company’s stock worth $1,439,472,000 after acquiring an additional 61,084,123 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Kenvue by 227.7% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 61,091,189 shares of the company’s stock valued at $1,226,711,000 after purchasing an additional 42,449,470 shares during the last quarter. Finally, Morgan Stanley increased its holdings in shares of Kenvue by 4,057.4% in the third quarter. Morgan Stanley now owns 31,162,614 shares of the company’s stock valued at $625,745,000 after purchasing an additional 30,413,040 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $19.58 on Friday. Kenvue has a 52 week low of $17.82 and a 52 week high of $27.80. The company has a fifty day simple moving average of $19.83 and a two-hundred day simple moving average of $20.16. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.03. Kenvue had a return on equity of 15.62% and a net margin of 9.87%. The firm had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. Kenvue’s revenue for the quarter was down 2.7% on a year-over-year basis. Sell-side analysts predict that Kenvue will post 1.15 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were given a dividend of $0.20 per share. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.